After thyroid eye drug scores in PhIII test, Horizon Pharma readies marketing application

Less than two years after Horizon Pharma $HZNP procured phase III-ready thyroid eye disease (TED) drug teprotumumab for $145 million upfront by acquiring a unit of Narrow River, biotech veteran David Madden’s investment firm — the bet has paid off, as the autoimmune inflammatory disorder drug passed its late-stage test on Thursday.